缬沙坦治疗原发性高血压伴高尿酸血症的临床观察  

Clinical observation of valsartan in the treatment of essential hypertension associated with hyperuricemia

作　　者：张金春[1] 

机构地区：[1]辽宁省普兰店市中心医院心血管二病房,辽宁普兰店116200

出　　处：《中国医药科学》2015年第4期52-53,62,共3页China Medicine And Pharmacy

摘　　要：目的探讨缬沙坦治疗原发性高血压伴高尿酸血症的临床疗效。方法 120例老年原发性高血压伴高尿酸血症患者,随机分为试验组与对照组,各60例。试验组给予缬沙坦,对照组给予硝苯地平缓释片,比较两组患者的疗效。结果治疗后两组患者SBP、DBP均较治疗前有明显降低(P<0.05),两组患者血压均降至正常,组间差异无统计学意义(P>0.05)。而试验组用药前尿酸(491.03±73.57)μmol/L,用药后尿酸(385.71±34.28)μmol/L,血尿酸明显下降(P<0.05)。硝苯地平缓释片血尿酸较用药前后差异无统计学意义。结论缬沙坦对伴高尿酸血症的原发性高血压患者疗效显著,安全、作用持久,值得临床推广应用。Objective To investigate the efficacy of valsartan in the treatment of essential hypertension associated with hyperuricemia. Methods 120 cases of elderly patients with essential hypertension associated with hyperuricemia were randomly divided into experimental group and control group, each group contained 60 cases. The treatment group was given valsartan, and the control group was given extended release nifedipine tablets. The effects of two groups were compared. Results After treatment, the SBP and DBP of two groups patients were decreased significantly（P〈0.05）. The blood pressures of two groups were decreased to normal, without significant difference between two groups（P〉0.05）. The uric acid of experimental group was（491.03±73.57）μmol/L before treatment, and that was（385.71±34.28）μmol/L after treatment. The concentration of the blood uric acid of experimental group was decreased significantly（P〈0.05）. In extended release nifedipine tablets group, the concentration of uric acid was no difference before and after treatment. Conclusion The valsartan in treatment of essential hypertension associated with hyperuricemia has obvious curative effect. It is safety, lasting effect, and worthy of clinical application.

关 键 词：原发性高血压 高尿酸血症 氯沙坦 

分 类 号：R544.1[医药卫生—心血管疾病]